Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Uk Mhra Gmp
  6. /
  7. STRIDES SHASUN LIMITED
Uk Mhra Gmp
•STRIDES SHASUN LIMITED•January 9, 2017

STRIDES SHASUN LIMITED – UK MHRA GMP Certificate UK API 20003 Insp GMP 20003/14223367-0001

Record Details

This Uk Mhra Gmp record concerns STRIDES SHASUN LIMITED, with an inspection on January 9, 2017, issued by the MHRA, covering drugs.

Company
STRIDES SHASUN LIMITED
Compliance status
GMPC
Certificate type
GMP
Inspection date
January 9, 2017
Issued
April 25, 2017
MIA number
UK API 20003
Site address
A-1/B SIPCOT INDUSTRIAL COMPLEX, KUDIKADU VILLAGE, CUDDALORE, IN-607 005, INDIA
Country
INDIA
Products
Human Medicinal Products
Manufacturing operations
[2000007813] RANITIDINE HYDROCHLORIDE [2000007870] VENLAFAXINE HYDROCHLORIDE [1000000402] NABUMETONE [1000007380] GABAPENTIN [1000007944] OLANZAPINE [1000009671] NIZATIDINE Active Substances 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES RANITIDINE HYDROCHLORIDE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Milling & sieving 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing VENLAFAXINE HYDROCHLORIDE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Milling & sieving 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing NABUMETONE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation & Purification 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Milling & sieving 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing GABAPENTIN 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation & Purification 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Milling & sieving 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing OLANZAPINE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation & Purification 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Milling & sieving 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing NIZATIDINE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture Of Active Substance Intermediates 3.1.2  Manufacture Of Crude Active Substance 3.1.3  Salt Formation/Purification steps (eg. Crystallisation) Crystallisation & Purification 3.5 General Finishing Steps 3.5.1  Physical Processing Steps Drying, Milling & sieving 3.5.2  Primary Packaging 3.5.3  Secondary Packaging 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing Any restrictions related to the scope of this certificate: Restrictions Building Room Line/equipment QC Testing Products Certification DOES NOT include Production Block 1.
View Company Profile

ID · d72137f5-e6c5-4f15-bf60-d91c24cb9da4

Other documents for STRIDES SHASUN LIMITED
  • 483 - 2026-05-20May 20, 2026
  • 483 - 2022-12-05December 5, 2022
  • 483 - 2019-05-24May 24, 2019
  • WARNING_LETTER - 2019-02-05February 5, 2019
  • 483 - 2017-05-26May 26, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore STRIDES SHASUN LIMITED
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.